Attero Solution
NDC Package 87143-100-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Attero (calcipotriene and betamethasone dipropionate) solution is aTTERO™ Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older.Additional pediatric use information is approved for LEO Pharma A/S's Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension. This formulation utilizes a solution delivery system. Marketed by Perfero Pharma, Inc., this product is identified by NDC 87143-100 and is authorized under FDA application ANDA210765.

Identification & Billing

NDC Package Code
87143-100-60
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 60 g in 1 BOTTLE, PLASTIC
Product Code
87143-100
11-Digit Billing Format
87143010060

Clinical Specifications

Proprietary Name
Attero
Non-Proprietary Name
Calcipotriene And Betamethasone Dipropionate
Substance Name
Betamethasone Dipropionate; Calcipotriene
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Pharmacologic Class
Usage Information
ATTERO™ Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older.Additional pediatric use information is approved for LEO Pharma A/S's Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension. However, due to LEO Pharma A/S's marketing exclusivity rights, this drug product is not labeled with that information.

Regulatory & Marketing

Labeler Name
Perfero Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA210765
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87143-100-60 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 60 g in 1 bottle, plastic of Attero, a human prescription drug labeled by Perfero Pharma, Inc.. This solution is formulated for topical use and contains betamethasone dipropionate; calcipotriene as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Perfero Pharma, Inc. on June 01, 2026. The current certification is valid through December 31, 2027.

How is this Perfero Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87143010060. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87143-100-60
11-Digit CMS (5-4-2)
87143-0100-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.